Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-009242
Filing Date
2025-07-15
Accepted
2025-07-15 16:15:50
Documents
37
Period of Report
2025-05-31

Document Format Files

Seq Description Document Type Size
1 10-Q bzyr-20250531x10q.htm   iXBRL 10-Q 467862
2 EX-31.1 bzyr-20250531xex31d1.htm EX-31.1 11726
3 EX-31.2 bzyr-20250531xex31d2.htm EX-31.2 11846
4 EX-32.1 bzyr-20250531xex32d1.htm EX-32.1 6584
5 EX-32.2 bzyr-20250531xex32d2.htm EX-32.2 7014
  Complete submission text file 0001558370-25-009242.txt   1907226

Data Files

Seq Description Document Type Size
6 EX-101.SCH bzyr-20250531.xsd EX-101.SCH 17628
7 EX-101.CAL bzyr-20250531_cal.xml EX-101.CAL 17717
8 EX-101.DEF bzyr-20250531_def.xml EX-101.DEF 40944
9 EX-101.LAB bzyr-20250531_lab.xml EX-101.LAB 136828
10 EX-101.PRE bzyr-20250531_pre.xml EX-101.PRE 88086
40 EXTRACTED XBRL INSTANCE DOCUMENT bzyr-20250531x10q_htm.xml XML 133259
Mailing Address 9432 KATY FREEWAY HOUSTON TX 77055
Business Address 12000 RICHMOND AVE HOUSTON TX 77082 (713) 335-5697
BURZYNSKI RESEARCH INSTITUTE INC (Filer) CIK: 0000724445 (see all company filings)

EIN.: 760136810 | State of Incorp.: DE | Fiscal Year End: 0228
Type: 10-Q | Act: 34 | File No.: 000-23425 | Film No.: 251124968
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)